Osborne Partners Capital Management LLC Lowers Position in Pfizer Inc. $PFE

Osborne Partners Capital Management LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 19.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 108,581 shares of the biopharmaceutical company’s stock after selling 26,270 shares during the quarter. Osborne Partners Capital Management LLC’s holdings in Pfizer were worth $3,049,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Kepler Cheuvreux Suisse SA purchased a new stake in shares of Pfizer during the 3rd quarter valued at $16,613,000. Mackenzie Financial Corp grew its position in Pfizer by 119.6% in the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. grew its position in Pfizer by 50.9% in the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after acquiring an additional 57,777 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after acquiring an additional 5,978,927 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in Pfizer during the third quarter valued at about $81,298,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on PFE shares. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Finally, CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer Stock Performance

NYSE PFE opened at $24.29 on Friday. The company has a 50-day simple moving average of $25.63 and a two-hundred day simple moving average of $26.23. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The firm has a market cap of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.